# REACT-SCOT Pharmacoepidemiology (REACT-SCOT-PHARM)

First published: 01/06/2020

**Last updated:** 21/11/2020





# Administrative details

EU PAS number
EUPAS35558
Study ID
38213
DARWIN EU® study
No
Study countries
United Kingdom
Study description
Observational analysis of the association of COVID-19 with drug exposures: A

### Study status

case control study in the population of Scotland

### Research institutions and networks

### **Institutions**

University of Edinburgh (UofE)
United Kingdom
First published: 23/11/2018
<b>Last updated:</b> 16/12/2024
Institution Educational Institution Hospital/Clinic/Other health care facility
ENCePP partner

Public Health Scotland Glasgow, Scotland

# Contact details

### Study institution contact

Helen Colhoun helen.colhoun@igmm.ed.ac.uk

Study contact

helen.colhoun@igmm.ed.ac.uk

### **Primary lead investigator**

Helen Colhoun

#### **Primary lead investigator**

# Study timelines

#### Date when funding contract was signed

Planned: 01/05/2020

Actual: 01/05/2020

#### Study start date

Planned: 01/03/2020 Actual: 01/03/2020

#### Data analysis start date

Planned: 01/05/2020 Actual: 01/05/2020

#### Date of interim report, if expected

Planned: 05/06/2020

#### Date of final study report

Planned: 12/06/2020

# Sources of funding

Other

# More details on funding

Public Health Scotland

# Regulatory

Was the study required by a regulator	y body?
---------------------------------------	---------

No

### Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

# Study type

# Study type list

### **Study type:**

Non-interventional study

### Scope of the study:

Disease epidemiology

### Main study objective:

A systematic examination of drug exposures and their association with severe COVID-19

# Study Design

### Non-interventional study design

Case-control

# Study drug and medical condition

#### Medical condition to be studied

COVID-19

# Population studied

#### Age groups

Term newborn infants (0 - 27 days)

Infants and toddlers (28 days - 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

#### **Estimated number of subjects**

30000

# Study design details

#### **Outcomes**

Severe COVID -19 defined as entry to critical care unit or death within of a positive nucleic acid test for SARS-CoV-2

### Data analysis plan

rate ratios estimated by conditional logistic regression

### **Documents**

#### Study, other information

bnfandicdvulnerablepharmacoepi.pdf (464.4 KB)

### **Study publications**

McKeigue PM, Weir A, Bishop J, McGurnaghan SJ, Kennedy S, McAllister D, Roberts...

# Data management

### **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### Data sources

#### Data sources (types)

Administrative healthcare records (e.g., claims)

Disease registry

Drug dispensing/prescription data

Other

### Data sources (types), other

ECOSS- virology laboratory data covering the population of Scotland.SICSAGdatabase of all Critical Care Unit AdmissionsPrescribing Information System Scotland- all national dispensed prescriptions. Scottish Morbidity Record 01- all national hospitalisations Rapid- daily hospitalisation returnsNational Records of

# Use of a Common Data Model (CDM)

### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

### **Check completeness**

Unknown

### **Check stability**

Unknown

### **Check logical consistency**

Unknown

### Data characterisation

#### **Data characterisation conducted**

No